The Enterprise Value as of September 2024 (TTM) for Pharvaris N.V. (PHVS) is 679.34M

According to Pharvaris N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 679.34M. This represents a change of -6.17% compared to the average of 724.02M of the last 4 quarters.

Pharvaris N.V. (PHVS) Historical Enterprise Value (quarterly & annually)

How has PHVS Enterprise Value performed in the past?

The mean historical Enterprise Value of Pharvaris N.V. over the last ten years is 353.68M. The current 679.34M Enterprise Value has changed 19.11% with respect to the historical average. Over the past ten years (40 quarters), PHVS's Enterprise Value was at its highest in in the December 2023 quarter at 935.64M. The Enterprise Value was at its lowest in in the April 2021 quarter at -55830646.42.

Pharvaris N.V. (PHVS) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Pharvaris N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Pharvaris N.V. (PHVS) Average Enterprise Value

How has PHVS Enterprise Value performed in the past?

The current Enterprise Value of Pharvaris N.V. (PHVS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Pharvaris N.V. (PHVS) Enterprise Value vs. Peers

How is PHVS’s Enterprise Value compared to its peers?

Pharvaris N.V.’s Enterprise Value is greater than PMV Pharmaceuticals, Inc. (41.69M), greater than Eliem Therapeutics, Inc. (331.55M), greater than MediciNova, Inc. (45.91M), greater than PepGen Inc. (253.77M), greater than Molecular Partners AG (-9779510.40), greater than Mineralys Therapeutics, Inc. (509.22M), greater than AN2 Therapeutics, Inc. (4.41M), greater than Monte Rosa Therapeutics, Inc. (284.72M), greater than Design Therapeutics, Inc. (272.10M), greater than Werewolf Therapeutics, Inc. (-5978336.00), greater than Ikena Oncology, Inc. (47.83M), greater than Stoke Therapeutics, Inc. (583.04M), less than Tyra Biosciences, Inc. (966.91M), greater than Anebulo Pharmaceuticals, Inc. (49.05M), less than Janux Therapeutics, Inc. (2.57B), greater than Rezolute, Inc. (282.08M),

Build a custom stock screener for Pharvaris N.V. (PHVS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Pharvaris N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Pharvaris N.V. (PHVS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Pharvaris N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.